目的 探究重组人脑利钠肽联合去乙酰毛花苷治疗急性心力衰竭患者的临床疗效和安全性。方法 选取2014年1月-2017年1月在昌江黎族自治县人民医院治疗的急性心力衰竭患者150例，随机分成对照组（75例）和治疗组（75例）。对照组患者静脉滴注去乙酰毛花苷注射液，0.4 mg溶于5%葡萄糖注射液10 mL中，10 min内滴注完毕，然后每2小时静脉滴注一次，直至患者急性左心衰症状完全缓解；治疗组患者在对照组的基础上静脉推注注射用重组人脑利钠肽，1.5 μg/kg负荷剂量，然后采用微量泵以0.01 μg/（kg·min）持续泵入。两组患者均治疗48 h。观察两组患者临床疗效，同时比较治疗前后两组患者收缩压、心室率、左心衰缓解时间、超敏C反应蛋白（hs-CRP）、同型半胱氨酸（Hcy）和N-末端脑钠肽前体（NT-proBNP）水平及不良反应情况。结果 治疗后，对照组和治疗组的总有效率分别为82.67%、94.67%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的收缩压、心室率均显著降低（P<0.05），且治疗组收缩压、心室率和左心衰缓解时间均显著低于对照组患者（P<0.05）。治疗后，两组患者hs-CRP、Hcy和NT-proBNP血清水平均显著降低（P<0.05），且治疗后治疗组患者hs-CRP、Hcy和NT-proBNP血清水平明显低于对照组（P<0.05）。治疗期间，治疗组患者不良反应的发生率为4.00%，显著低于对照组的14.67%，两组比较差异具有统计学意义（P<0.05）。结论 重组人脑利钠肽联合去乙酰毛花苷治疗急性心力衰竭疗效显著，不良反应发生率低，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of recombinant human brain natriuretic peptide combined with deslanoside in treatment of acute heart failure. Methods Patients (150 cases) with acute heart failure in Changjiang Lizu Autonomous County People's Hospital from January 2014 to January 2017 were randomly divided into control (75 cases) and treatment (75 cases) groups. Patients in the control group were iv administered with Deslanoside Injection, 0.4 g added into 5% glucose injection 100 mL, and dripping time less than 10 min, then once every 2 h until the acute left heart failure symptom were completely relieved. Patients in the treatment group were iv administered with Recombinant Human Brain Natriuretic Peptide for injection on the basis of the control group, 1.5 μg/kg as the loading dose, then used a micro pump to pump continuously at the speed of 0.01 μg/(kg·min). Patients in two groups were treated for 48 h. After treatment, the clinical efficacy was evaluated, and the systolic blood pressure, ventricular rate, and remission time of left ventricular failure, the serum levels of hs-CRP, Hcy, and NT-proBNP, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.67% and 94.67% respectively, and there were differences between two groups (P < 0.05). After treatment, the systolic blood pressure and ventricular rate in two groups were significantly decreased (P < 0.05), and the systolic blood pressure, ventricular rate, and remission time of left ventricular failure in the treatment group after treatment were significantly lower than those in the control group (P < 0.05). After treatment, the serum hs-CRP, HCY and NT-proBNP levels in two groups were significantly decreased (P < 0.05), and the hs-CRP, HCY and NT-proBNP levels in the treatment group after treatment were significantly lower than those in the control group (P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 4.00%, which was significantly lower than 14.67% in the control group, with significant difference between two groups (P < 0.05). Conclusion recombinant human brain natriuretic peptide combined with deslanoside in treatment of acute heart failure has significant clinical effect with lower adverse reactions incidence, which has a certain clinical application value.